| 322 |
increased |
acetylcholine receptor activator activity
(GO:0030549)
|
Nicotinic acetylcholine receptor
(FMA:61796)
|
663: Desensitization, Nicotinic acetylcholine receptor
|
| 487 |
decreased |
nitric oxide biosynthetic process
(GO:0006809)
|
nitric oxide
(CHEBI:16480)
|
933: KE6 : Depletion, Nitric Oxide
|
| 121 |
decreased |
|
nitric oxide
(CHEBI:16480)
|
193: Decreased, Nitric Oxide
|
| 160 |
decreased |
nitric-oxide synthase activity
(GO:0004517)
|
nitric oxide synthase, brain
(PR:000011326)
|
147: Inhibition, Inducible Nitric Oxide Synthase by Metabolite CGA 265307
|
| 485 |
decreased |
catalytic activity
(GO:0003824)
|
nitric oxide synthase, endothelial
(PR:000011328)
|
973: KE5 : Decrease, AKT/eNOS activity
|
| 492 |
increased |
protein glutathionylation
(GO:0010731)
|
nitric oxide synthase, endothelial
(PR:000011328)
|
927: KE1 : S-Glutathionylation, eNOS
|
| 494 |
functional change |
|
nitric oxide synthase, endothelial
(PR:000011328)
|
932: KE4 : Uncoupling, eNOS
|
| 806 |
increased |
NLRP3 inflammasome complex assembly
(GO:0044546)
|
NLRP3 inflammasome complex
(GO:0072559)
|
1895: NLRP3 inflammasome activity, increased
|
| 685 |
decreased |
NMDA glutamate receptor activity
(GO:0004972)
|
NMDA selective glutamate receptor complex
(GO:0017146)
|
195: Inhibition, NMDARs
|
| 686 |
increased |
NMDA glutamate receptor activity
(GO:0004972)
|
NMDA selective glutamate receptor complex
(GO:0017146)
|
388: Overactivation, NMDARs
|
| 1085 |
increased |
wounding
(MP:0013027)
|
Nose
(FMA:46472)
|
2312: Increased, nasal lesions
|
| 1090 |
decreased |
response to odorant
(GO:1990834)
|
Nose
(FMA:46472)
|
2317: Loss of olfactory function
|
| 224 |
abnormal |
DNA alkylation
(GO:0006305)
|
Nuclear deoxyribonucleic acid
(FMA:67194)
|
373: Formation, Pro-mutagenic DNA Adducts
|
| 228 |
functional change |
DNA repair
(GO:0006281)
|
Nuclear deoxyribonucleic acid
(FMA:67194)
|
493: Increased, Insufficient repair or mis-repair of pro-mutagenic DNA adducts
|
| 254 |
increased |
signaling
(GO:0023052)
|
nuclear factor erythroid 2-related factor 2
(PR:000011170)
|
478: Activation, NRF2
|
| 18 |
increased |
gene expression
(GO:0010467)
|
nuclear hormone receptor FTZ-F1 (fruit fly)
(PR:P33244)
|
1265: Decrease, Fushi tarazu factor-1 gene expression
|
| 24 |
increased |
transcription corepressor activity
(GO:0003714)
|
nuclear receptor corepressor 1
(PR:000011047)
|
1000: stabilization, PPAR alpha co-repressor
|
| 23 |
increased |
transcription corepressor activity
(GO:0003714)
|
nuclear receptor corepressor 2
(PR:000011048)
|
1000: stabilization, PPAR alpha co-repressor
|
| 256 |
increased |
signaling
(GO:0023052)
|
nuclear receptor subfamily 0 group B member 2
(PR:000011391)
|
480: Activation, SHP
|
| 37 |
increased |
signaling
(GO:0023052)
|
nuclear receptor subfamily 1 group I member 2
(PR:000011397)
|
2 Events
|
| 38 |
increased |
signaling
(GO:0023052)
|
nuclear receptor subfamily 1 group I member 3
(PR:000011398)
|
715: Activation, Constitutive androstane receptor
|
| 244 |
decreased |
signaling
(GO:0023052)
|
nuclear receptor subfamily 1 group I member 3
(PR:000011398)
|
456: Suppression, Constitutive androstane receptor, NR1I3
|
| 586 |
decreased |
transport
(GO:0006810)
|
nutrient
(CHEBI:33284)
|
1132: Blood loss and development of anemia, Impaired oxygen delivery and nutrient delivery to tissue, impaired carbon dioxide and waste product removal
|
| 460 |
increased |
atrophy
(MESH:D001284)
|
olfactory epithelium
(UBERON:0001997)
|
868: Increase, Tissue Degeneration, Necrosis & Atrophy
|
| 463 |
increased |
neoplasm
(MP:0002006)
|
olfactory segment of nasal mucosa
(UBERON:0005386)
|
872: Increase, Site of Contact Nasal Tumors
|